Feb 23, 2026 09:36AM
Jan 14, 2026 10:39AM
May 7, 2024 08:00AM
Jan 2, 2024 06:00AM
Jan 2, 2024 06:00AM
Aug 11, 2023 09:00PM
Aug 6, 2023 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against UP Fintech, GDS, Arrow, and ImmunityBio and Encourages Investors to Contact the Firm
Jul 31, 2023 09:00PM
Jul 26, 2023 09:00PM
Feb 15, 2022 09:00AM
Feb 14, 2022 05:18PM
Feb 14, 2022 05:17PM
Jan 19, 2022 05:23AM
Jan 18, 2022 06:00PM ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Sur
Jan 12, 2022 08:32AM
Jan 12, 2022 08:30AM
Dec 20, 2021 09:00AM
Nov 8, 2021 04:11PM
Nov 4, 2021 09:00AM
Oct 19, 2021 09:02AM
Oct 19, 2021 09:00AM ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
Oct 13, 2021 09:00AM
Oct 4, 2021 08:30AM
Sep 13, 2021 08:32AM
Sep 13, 2021 08:30AM
Sep 7, 2021 08:30AM
Sep 1, 2021 09:00AM
Aug 16, 2021 09:05AM ImmunityBio (IBRX) Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer
Aug 16, 2021 09:00AM
Jul 27, 2021 09:00AM
Jul 14, 2021 09:06AM
Jul 14, 2021 09:00AM
Jun 28, 2021 09:00AM
Jun 23, 2021 04:05PM
Jun 15, 2021 07:06AM ImmunityBio (IBRX) Announces FDA Authorizes its Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer
Jun 15, 2021 07:00AM
Jun 10, 2021 09:08AM
Jun 10, 2021 09:00AM
May 25, 2021 09:03AM
May 25, 2021 09:00AM
May 24, 2021 09:00AM
May 20, 2021 09:00AM ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Faile
May 17, 2021 09:05AM
May 17, 2021 09:00AM
May 13, 2021 08:00AM
May 4, 2021 09:05AM
May 4, 2021 09:00AM
Apr 29, 2021 09:00AM
Apr 22, 2021 09:00AM ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications
Apr 8, 2021 09:02AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All